Clinical, behavioural and pharmacogenomic factors influencing the response to levothyroxine therapy in patients with diagnosed primary hypothyroidism

Rosie Dew, Scott Wilkes, Onyebuchi Okosieme, Colin Dayan, Vinay Eligar, Simon Pearce, Salman Razvi

Citation

Review question(s)
To what extent do clinical, behavioural and pharmacogenomic factors affect the response to levothyroxine therapy in patients with primary hypothyroidism?

Searches
The following databases will be searched: Web of Science, MEDLINE (Ovid) and PubMed.

Any publication period will be used, and language will be restricted to English only. Articles will also be identified from reference lists.

Types of study to be included
All potential studies will be initially accepted; RCTs, case studies, observational studies, retrospective audits etc.

Condition or domain being studied
Overt or subclinical hypothyroidism and TSH levels

Participants/ population
Inclusion criteria: Adults aged 18 or older, with history of hypothyroidism and receiving levothyroxine treatment.

Exclusion criteria: Children (aged less than 18 years), patients on other forms of hormone replacement therapy or combination therapy, pregnant women, patients with secondary hypothyroidism, patients previously treated for hyperthyroidism.

Intervention(s), exposure(s)
Clinical, behavioural and pharmacogenomic interventions. Any intensity and frequency with length of intervention greater than 6 weeks.

Comparator(s)/ control
A control or comparative group is necessary. This can be placebo/no treatment/standard therapy/ usual care/ alternative treatment.

Outcome(s)
Primary outcomes
The quantitative effect of clinical/ behavioural/pharmacogenomic factors on TSH levels.

Secondary outcomes
Effects on T4 and T3 levels, any short term effects, mortality, morbidity, quality of life, treatment complications, adverse effects, physical functioning, social functioning.

Data extraction, (selection and coding)
Studies will be screened through reading the title, abstract and then full text. Two reviewers will independently participate in the extraction of data and the selection of articles. If there is disagreement between the reviewers, a third reviewer will be consulted.

The following data will be extracted from articles that meet the inclusion criteria:

1) Authors, year of publication, country, study design, number of patients
2) Population demographics
3) Reason for hypothyroidism
4) Co-morbidities
5) Levothyroxine dose – range/average
6) TSH levels
7) Intervention; type, duration etc.

**Risk of bias (quality) assessment**
Articles will be assessed referring to the GRADE guidelines. Two reviewers will assess articles for quality to reduce bias. Any disagreement will be resolved by consulting with a third reviewer.

**Strategy for data synthesis**
A four-phase flow diagram will be created depicting the search strategy used during the review, and the numbers of articles excluded and included, and on what basis (PRISMA). A combined narrative synthesis of the findings from the included studies will be provide. A summary of the difference between the mean TSH levels of patients from various interventions will be presented. A summary of the effect of various attributes affecting TSH control will be presented. Descriptive summary tables will also be created.

**Analysis of subgroups or subsets**
None planned

**Dissemination plans**
Findings will be disseminated at conferences and in professional and peer-reviewed journals.

**Contact details for further information**
Dr Dew
Department of Pharmacy, Health and Wellbeing
Sciences Complex
City Campus
Chester Road
Sunderland
SR1 3SD
University of Sunderland
rosie.dew@sunderland.ac.uk

**Organisational affiliation of the review**
University of Sunderland

http://www.sunderland.ac.uk/faculties/apsc/ourdepartments/phw/

**Review team**
Dr Rosie Dew, University of Sunderland
Professor Scott Wilkes, University of Sunderland
Dr Onyebuchi Okosieme, Cardiff University School of Medicine
Professor Colin Dayan, Cardiff University School of Medicine
Dr Vinay Eligar, Cardiff University School of Medicine
Professor Simon Pearce, Institute of Human Genetics
Dr Salman Razvi, Queen Elizabeth Hospital

**Anticipated or actual start date**
01 October 2015

**Anticipated completion date**
06 June 2016

**Funding sources/sponsors**
Not applicable

**Conflicts of interest**
None known

**Language**
English

**Country**
England, Wales

**Subject index terms status**
Subject indexing assigned by CRD

**Subject index terms**
Humans; Hypothyroidism; Pharmacogenetics; Thyrotropin; Thyroxine

**Stage of review**
Ongoing

**Date of registration in PROSPERO**
15 December 2015

**Date of publication of this revision**
15 December 2015

**Stage of review at time of this submission**

<table>
<thead>
<tr>
<th>Stage of review at time of this submission</th>
<th>Started</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preliminary searches</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Piloting of the study selection process</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Formal screening of search results against eligibility criteria</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Data extraction</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Risk of bias (quality) assessment</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Data analysis</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>